argenx SE (ARGX)
605.92
+9.18
(+1.54%)
USD |
NASDAQ |
Nov 22, 16:00
597.01
-8.91
(-1.47%)
After-Hours: 20:00
argenx Gross Profit Margin (Quarterly): 89.70% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 89.70% |
| June 30, 2024 | 89.03% |
| March 31, 2024 | 89.23% |
| December 31, 2023 | 90.30% |
| September 30, 2023 | 89.08% |
| June 30, 2023 | 91.12% |
| Date | Value |
|---|---|
| March 31, 2023 | 91.63% |
| December 31, 2022 | 92.66% |
| September 30, 2022 | 92.56% |
| June 30, 2022 | 93.34% |
| March 31, 2022 | 94.14% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
89.03%
Minimum
Jun 2024
94.14%
Maximum
Mar 2022
91.16%
Average
91.12%
Median
Jun 2023
Gross Profit Margin (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| uniQure NV | 55.36% |
| ProQR Therapeutics NV | -- |
| Akari Therapeutics PLC | -- |
| Merus NV | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Profit Margin (Quarterly) | 15.95% |
| Operating Margin (Quarterly) | 2.82% |